Richard S.E. Keefe

NeuroCog Trials, Inc.

Affiliated withNeuroCog Trials, Inc.Duke University Medical Center

Research Area

Biography

Richard S.E. Keefe has not added Biography.
If you are Richard S.E. Keefe and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 25	2014

Other Publications

Article	Year
Sensory acuity and reasoning in delusional disorder. Comprehensive psychiatry\| PubMed ID: 11994833	2002
Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources. Schizophrenia research\| PubMed ID: 12165376	2002
Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications. Psychopharmacology\| PubMed ID: 12759802	2003
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophrenia bulletin\| PubMed ID: 12908660	2003
Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. The Journal of clinical psychiatry\| PubMed ID: 15096076	2004
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia research\| PubMed ID: 15099610	2004
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperid... The American journal of psychiatry\| PubMed ID: 15169686	2004
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biological psychiatry\| PubMed ID: 15336511	2004
Defining a cognitive function decrement in schizophrenia. Biological psychiatry\| PubMed ID: 15780858	2005
Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of general psychiatry\| PubMed ID: 15809403	2005
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia bulletin\| PubMed ID: 15888422	2005
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophrenia research\| PubMed ID: 16125372	2005
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biological psychiatry\| PubMed ID: 16140282	2006
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia research\| PubMed ID: 16171976	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine\| PubMed ID: 16172203	2005
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophrenia research\| PubMed ID: 16202565	2006
Measuring outcome priorities and preferences in people with schizophrenia. The British journal of psychiatry : the journal of mental science\| PubMed ID: 16319405	2005
The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome. Journal of clinical and experimental neuropsychology\| PubMed ID: 16484097	2006
The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. The American journal of psychiatry\| PubMed ID: 16513863	2006
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American journal of psychiatry\| PubMed ID: 16585434	2006
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. The American journal of psychiatry\| PubMed ID: 16585435	2006
Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring. Schizophrenia research\| PubMed ID: 16626938	2006
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology\| PubMed ID: 16641947	2006
Insight in first-episode psychosis. Psychological medicine\| PubMed ID: 16740175	2006
Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatric services (Washington, D.C.)\| PubMed ID: 16870959	2006
A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophrenia research\| PubMed ID: 16930949	2006
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. The American journal of psychiatry\| PubMed ID: 17151158	2006
NCAM1 and neurocognition in schizophrenia. Biological psychiatry\| PubMed ID: 17161382	2007
Risperidone and cognitive function in children with disruptive behavior disorders. Biological psychiatry\| PubMed ID: 17210137	2007
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. The American journal of psychiatry\| PubMed ID: 17329466	2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American journal of psychiatry\| PubMed ID: 17329467	2007
Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients. European psychiatry : the journal of the Association of European Psychiatrists\| PubMed ID: 17434715	2007
AKT1 and neurocognition in schizophrenia. The Australian and New Zealand journal of psychiatry\| PubMed ID: 17464696	2007
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of general psychiatry\| PubMed ID: 17548746	2007
How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophrenia bulletin\| PubMed ID: 17567627	2007
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. The American journal of psychiatry\| PubMed ID: 17606658	2007
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled t... Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology\| PubMed ID: 17625502	2008
Cognition as an outcome measure in schizophrenia. The British journal of psychiatry. Supplement\| PubMed ID: 18019044	2007
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. The American journal of psychiatry\| PubMed ID: 18172017	2008
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. The American journal of psychiatry\| PubMed ID: 18172018	2008
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. The American journal of psychiatry\| PubMed ID: 18172019	2008
Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. The journal of behavioral health services & research\| PubMed ID: 18246429	2008
Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. Journal of the International Neuropsychological Society : JINS\| PubMed ID: 18282319	2008
Cognitive deficits in patients with schizophrenia: effects and treatment. The Journal of clinical psychiatry\| PubMed ID: 18284272	2007
The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics\| PubMed ID: 18286587	2008
Relationship of cognition and psychopathology to functional impairment in schizophrenia. The American journal of psychiatry\| PubMed ID: 18450928	2008
What CATIE found: results from the schizophrenia trial. Psychiatric services (Washington, D.C.)\| PubMed ID: 18451005	2008
Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World psychiatry : official journal of the World Psychiatric Association (WPA)\| PubMed ID: 18458774	2008
Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophrenia research\| PubMed ID: 18495435	2008
Implementation considerations for multisite clinical trials with cognitive neuroscience tasks. Schizophrenia bulletin\| PubMed ID: 18495645	2008
Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. Journal of clinical and experimental neuropsychology\| PubMed ID: 18720182	2009
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Schizophrenia research\| PubMed ID: 18774696	2008
Extrapyramidal side-effects of antipsychotics in a randomised trial. The British journal of psychiatry : the journal of mental science\| PubMed ID: 18827289	2008
Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophrenia research\| PubMed ID: 19013769	2009
CMINDS does not have identical tests to the CATIE and MATRICS batteries. Commentary on O'Halloran et al. Schizophrenia research\| PubMed ID: 19013770	2009
Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia research\| PubMed ID: 19027269	2009
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. European journal of human genetics : EJHG\| PubMed ID: 19156168	2009
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS genetics\| PubMed ID: 19197363	2009
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology\| PubMed ID: 19339966	2009
Psychosocial factors in the neurobiology of schizophrenia: a selective review. Annals of the Academy of Medicine, Singapore\| PubMed ID: 19521639	2009
Measuring memory-prediction errors and their consequences in youth at risk for schizophrenia. Annals of the Academy of Medicine, Singapore\| PubMed ID: 19521641	2009
Memory-prediction errors and their consequences in schizophrenia. Neuropsychology review\| PubMed ID: 19575296	2009
Cognition and schizophrenia: is there a role for cognitive assessments in diagnosis and treatment? Psychiatry (Edgmont (Pa. : Township))\| PubMed ID: 19724777	2008
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia research\| PubMed ID: 19766459	2009
A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophrenia bulletin\| PubMed ID: 19776205	2011
Anticipating DSM-V: opportunities and challenges for cognition and psychosis. Schizophrenia bulletin\| PubMed ID: 19923191	2010
Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. The American journal of psychiatry\| PubMed ID: 20048021	2010
Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology\| PubMed ID: 20090669	2010
Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophrenia bulletin\| PubMed ID: 20194249	2011
Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort. Archives of general psychiatry\| PubMed ID: 20368509	2010
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophrenia bulletin\| PubMed ID: 20410237	2011
The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia. Psychiatry research\| PubMed ID: 20451258	2010
No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics\| PubMed ID: 20468059	2010
Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Archives of general psychiatry\| PubMed ID: 20530007	2010
The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition. Schizophrenia research\| PubMed ID: 20542412	2010
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. The Journal of clinical psychiatry\| PubMed ID: 20816031	2011
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. The Journal of clinical psychiatry\| PubMed ID: 20816042	2010
Differential effects of emotional information on interference task performance across the life span. Frontiers in aging neuroscience\| PubMed ID: 20953250	2010
Missing the sweet spot disengagement in schizophrenia. Psychiatry (Edgmont (Pa. : Township))\| PubMed ID: 20975816	2006
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophrenia research\| PubMed ID: 21075600	2011
Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology\| PubMed ID: 21107309	2011
Criminal justice system involvement among people with schizophrenia. Community mental health journal\| PubMed ID: 21113799	2011
Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology\| PubMed ID: 21116261	2011
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biological psychiatry\| PubMed ID: 21145041	2011
The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophrenia research\| PubMed ID: 21159492	2011
Methodological issues in negative symptom trials. Schizophrenia bulletin\| PubMed ID: 21270473	2011
Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophrenia research\| PubMed ID: 21277745	2011
Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia. Psychological assessment\| PubMed ID: 21381848	2011
Comprehensive model of how reality distortion and symptoms occur in schizophrenia: could impairment in learning-dependent predictive perception account for the manifestations of schizophreni... Psychiatry and clinical neurosciences\| PubMed ID: 21447049	2011
Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. Schizophrenia research\| PubMed ID: 21561740	2011
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. The American journal of psychiatry\| PubMed ID: 21572163	2011
Substance use and schizophrenia: adverse correlates in the CATIE study sample. Schizophrenia research\| PubMed ID: 21872443	2011
The Singapore flagship programme in translational and clinical research in psychosis. Early intervention in psychiatry\| PubMed ID: 22032547	2011
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophrenia bulletin\| PubMed ID: 22114098	2013
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophrenia research\| PubMed ID: 22169248	2012
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophrenia bulletin\| PubMed ID: 22290266	2013
The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition. Schizophrenia bulletin\| PubMed ID: 22328641	2013
Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia. The American journal of psychiatry\| PubMed ID: 22476674	2012
A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Schizophrenia research\| PubMed ID: 22483162	2012
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. The Journal of clinical psychiatry\| PubMed ID: 22687548	2012
Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. Psychiatry research\| PubMed ID: 22841345	2012
Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 22927402	2012
Cognitive impairment in schizophrenia. Handbook of experimental pharmacology\| PubMed ID: 23027411	2012
Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study. Schizophrenia research\| PubMed ID: 23040735	2012
How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS. Cognitive neuropsychiatry\| PubMed ID: 23145794	2013
Formulation of the age-education index: measuring age and education effects in neuropsychological performance. Psychological assessment\| PubMed ID: 23148648	2013
The course of cognitive functioning over six months in individuals at clinical high risk for psychosis. Psychiatry research\| PubMed ID: 23159196	2013
Applicability of the MATRICS Consensus Cognitive Battery in Singapore. The Clinical neuropsychologist\| PubMed ID: 23362823	2013
Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. Schizophrenia research\| PubMed ID: 23510596	2013
Cognition in schizophrenia: summary Nice Consultation Meeting 2012. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology\| PubMed ID: 23684476	2013
Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. The American journal of psychiatry\| PubMed ID: 23771174	2013
Altered Striatal Functional Connectivity in Subjects With an At-Risk Mental State for Psychosis. Schizophrenia bulletin\| PubMed ID: 23861539	2013
Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials. Innovations in clinical neuroscience\| PubMed ID: 23882433	2013
Brief Assessment of Cognition in Schizophrenia: Normative Data in an English-Speaking Ethnic Chinese Sample. Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists\| PubMed ID: 23912998	2013
Schizophrenia is a cognitive illness: time for a change in focus. JAMA psychiatry\| PubMed ID: 23925787	2013
Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis. Schizophrenia research\| PubMed ID: 24012459	2013
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia research\| PubMed ID: 24028744	2013
Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study. The American journal of psychiatry\| PubMed ID: 24030246	2014
Microvascular abnormality in schizophrenia as shown by retinal imaging. The American journal of psychiatry\| PubMed ID: 24030514	2013
Preserved working memory and altered brain activation in persons at risk for psychosis. The American journal of psychiatry\| PubMed ID: 24077560	2013
Elevated Antisaccade Error Rate as an Intermediate Phenotype for Psychosis Across Diagnostic Categories. Schizophrenia bulletin\| PubMed ID: 24080895	2013
Unraveling the relationship between obesity, schizophrenia and cognition. Schizophrenia research\| PubMed ID: 24119725	2013
The Longitudinal Youth at Risk Study (LYRIKS)--an Asian UHR perspective. Schizophrenia research\| PubMed ID: 24139196	2013
Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls. Psychiatry and clinical neurosciences\| PubMed ID: 24552637	2014